Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities

Abstract

The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate.

1 . An oral nutritional and therapeutic composition, comprising a unit dosage or serving mixture of from about 5 milligrams to about 100 milligrams magnesium, on an elemental basis, in the form of pharmaceutical quality magnesium R-(+)-alpha-lipoate having greater than 95% purity and greater than 95% chiral purity. 
     
     
         2 . A method of promoting the assimilation of blood sugar in human tissues, comprising administering to a human, by mouth, a safe and effective amount of pharmaceutical quality magnesium R-(+)-alpha-lipoate having greater than 95% purity and greater than 95% chiral purity. 
     
     
         3 . A method of preventing or treating sequelae, complications, and co-morbidities of a metabolic disorder related to impaired mitochondrial glycolysis in a human, comprising administering to said human a safe and effective amount of magnesium R-(+)-alpha-lipoate having greater than 95% purity and greater than 95% chiral purity. 
     
     
         4 . A method of preventing or treating insulin resistance in a mammal, comprising administering to said mammal a safe and effective amount of magnesium R-(+)-alpha-lipoate having greater than 95% purity and greater than 95% chiral purity.